Apriem Advisors boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 7.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 202,167 shares of the biopharmaceutical company’s stock after acquiring an additional 13,615 shares during the period. Pfizer accounts for 3.1% of Apriem Advisors’ holdings, making the stock its 5th biggest position. Apriem Advisors’ holdings in Pfizer were worth $8,825,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the stock. Nicola Wealth Management LTD. grew its holdings in Pfizer by 21.1% during the third quarter. Nicola Wealth Management LTD. now owns 169,900 shares of the biopharmaceutical company’s stock valued at $8,322,000 after purchasing an additional 29,600 shares during the period. Madrona Financial Services LLC bought a new position in Pfizer during the third quarter valued at $214,000. Twin Capital Management Inc. grew its holdings in Pfizer by 6.6% during the third quarter. Twin Capital Management Inc. now owns 618,477 shares of the biopharmaceutical company’s stock valued at $27,257,000 after purchasing an additional 38,027 shares during the period. Doyle Wealth Management grew its holdings in Pfizer by 0.6% during the third quarter. Doyle Wealth Management now owns 519,811 shares of the biopharmaceutical company’s stock valued at $22,908,000 after purchasing an additional 2,912 shares during the period. Finally, Zeke Capital Advisors LLC grew its holdings in Pfizer by 0.8% during the third quarter. Zeke Capital Advisors LLC now owns 187,642 shares of the biopharmaceutical company’s stock valued at $8,269,000 after purchasing an additional 1,450 shares during the period. 71.88% of the stock is owned by institutional investors.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $42.83, for a total value of $642,450.00. Following the sale, the insider now owns 124,994 shares in the company, valued at $5,353,493.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Pfizer Inc purchased 50,000 shares of the stock in a transaction on Monday, May 13th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.10. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The company had revenue of $13.12 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same quarter last year, the business posted $0.77 earnings per share. The firm’s revenue was up 1.6% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.89 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 7th. Investors of record on Friday, May 10th were given a $0.36 dividend. The ex-dividend date was Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.37%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
PFE has been the topic of several recent research reports. Goldman Sachs Group initiated coverage on Pfizer in a research report on Tuesday, May 28th. They set a “conviction-buy” rating on the stock. Credit Suisse Group restated a “buy” rating and set a $48.00 target price on shares of Pfizer in a research report on Monday, May 6th. Citigroup restated a “neutral” rating and set a $41.00 target price on shares of Pfizer in a research report on Wednesday, February 20th. JPMorgan Chase & Co. set a $46.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, April 30th. Finally, Barclays restated a “hold” rating and set a $41.00 target price on shares of Pfizer in a research report on Thursday, May 9th. Thirteen analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $46.00.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: Trade War
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.